Trials / Recruiting
RecruitingNCT06380816
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 167 (estimated)
- Sponsor
- Cancer Research UK · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells. The four main aims of the clinical trial are to find out: 1. The best dose of UCB4594 that can be given safely to participants in the trial. 2. What the side effects of UCB4594 are and how they can be managed. 3. What happens to UCB4594 inside the body and how it affects cancer cells. 4. Whether UCB4594 can cause cancer to shrink.
Detailed description
What does the study involve? This clinical trial is split into two phases. Phase I (Module A) is the 'dose escalation' phase. This is where small groups of participants receive UCB4594 at a certain dose level starting with a low dose level. After reviewing the results obtained at each dose level, it will be decided whether or how much to increase the dose for the next group of participants. This part of the study aims to find the best dose to give that does not cause too many side effects. Phase II is the 'dose expansion' phase. This starts when the dose escalation phase has worked out the best dose of UCB4594 to give. In this part of the trial UCB4594 will be given alone (Module B) or in combination with other anti-cancer drugs (Module C). This will allow us to find out more about how the drug is working and whether UCB4594 affects cancer. Details for Module C of the dose expansion phase will be added when the types of cancer and anti-cancer drugs are defined. What are the possible benefits and risks of participating? UCB4594 is a new drug that has never been given to humans before. Possible risks and benefits are based on laboratory tests and experience with similar drugs but there is not yet any information about the effects of UCB4594 in humans. Participants in the trial will be monitored closely to find out the effects of UCB4594.
Conditions
- Advanced Solid Tumours
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Triple Negative Breast Neoplasms
- Carcinoma, Renal Cell (Clear Cell Only)
- Esophageal Neoplasms
- Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)
- Uterine Cervical Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UCB4594 | Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year). |
Timeline
- Start date
- 2024-07-09
- Primary completion
- 2029-11-01
- Completion
- 2029-11-01
- First posted
- 2024-04-24
- Last updated
- 2024-08-20
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT06380816. Inclusion in this directory is not an endorsement.